Novart acquires Admune Pharmaceuticals to improve its line of cancer immunotherapy products

On October 26th Novarma announced two big positive news: the acquisition of Admune Pharmaceuticals and the acquisition of one of its IL-15 astrists for the treatment of metastasis cancer. The other is to obtain the experimental drug PBF-509 and XOMA pharmaceutical TGF-? Antibody research series research and development and marketing authorization.
Has been focusing on the development of anti-tumor product lines, especially cancer immunotherapy drug research and development has achieved a number of results, including: checkpoint inhibitors, chimeric antigen-modified T-cell immunotherapy (CART), T-cell immunoprotein mucosa molecule-3 (TIM-3) inhibitors, glucosin-induced tumor necrotogenic agent (GITR) astrologists, bone marrow cell targeting drugs and interferon gene stimulants (STING) stimulants. At present, Novarma has four drug candidates have entered the clinical trial stage, namely: bone marrow cell targeted drug series MCS-110, PD-1 checkpoint inhibitor PDR001, LAG-3 checkpoint inhibitor LAG525, the above three drugs have now entered phase I clinical trial stage, CART product line CTL019 has entered Phase II clinical. In addition, five other drug candidates are expected to enter clinical trials by the end of 2016, such as TIM-3 inhibitor MGB453, STING astrist MIW815 and GITR astrist.
highlight of this Admune acquisition is its IL-15 astration research series for the treatment of metastasis cancer. Preclinical trial results show that IL-15 agonist therapy can effectively activate CD8 plus, CD4 plus memory T cells and natural killer cells (NK cells), and thus activate the body's immune system.
studies have shown that adenosine and TGF-? In the tumor micro-environment has an immunosuppressive effect, so that tumor cells escape the identification and attack of immune cells. Around these two targets, Palobiofarma Pharmaceuticals has developed adenosine subjectant antagonist PBF-509, and XOMA Pharmaceuticals has developed the corresponding TGF-? Antibodies, through in-depth collaboration with Novaral in the future, may become promising cancer immunotherapy.
PBF-509 project is the most powerful licensing agreement in the history of biotechnology in Spain, and we are proud of it," said Julio Castro, CEO of Palobiofarma, a company in The People's Bank of China. We firmly believe that our cooperation with Novart will further facilitate substantial research and development progress. (Bio Valley)